Core Insights - Johnson & Johnson (JNJ) reported strong fourth-quarter 2025 results, with total revenues increasing by 9.1% to $24.56 billion and adjusted EPS rising by 20.6% year over year to $2.46 [1][10] - The company expects sales in 2026 to be between $100 billion and $101 billion, with adjusted EPS projected in the range of $11.43 to $11.63 [3][10] Innovative Medicines Segment - Despite the loss of exclusivity for Stelara, sales in the Innovative Medicines unit grew by 10.0% year over year to $15.76 billion in Q4 2025 [2][10] - The segment achieved over $60 billion in full-year sales for the first time in 2025, with 13 brands experiencing double-digit growth [6] - J&J anticipates continued growth in the Innovative Medicine segment in 2026, driven by key products and new launches, expecting a growth rate of 5% to 7% from 2025 to 2030 [7][10] MedTech Segment - The MedTech segment saw sales rise by 7.5% to $8.8 billion in Q4 2025, supported by strong performance in Cardiovascular, Surgery, and Vision [2][10] - J&J expects improved growth in the MedTech business in 2026, driven by new product launches across its portfolios [15][10] - The potential separation of the Orthopaedics franchise into a standalone company is expected to enhance growth and margins for the MedTech unit [14] Research and Development - J&J invested over $32 billion in R&D and M&A in 2025, including acquisitions that expanded its product portfolio [8] - The company achieved significant clinical and regulatory milestones, gaining approvals for new products that are expected to drive growth [9] Legal and Market Challenges - J&J faces challenges from the loss of patent exclusivity for Stelara, which accounted for approximately 18% of the Innovative Medicine unit's sales in 2024 [17] - The company is also dealing with the impact of the Medicare Part D redesign and ongoing legal battles related to its talc-based products [19][20] Stock Performance and Valuation - JNJ's stock has outperformed the industry, rising 48.5% over the past year compared to a 20.0% increase in the industry [23] - The stock is currently trading at a price/earnings ratio of 19.36, slightly above the industry average [25] - Earnings estimates for 2026 have increased, reflecting J&J's optimistic financial outlook [27] Overall Outlook - J&J's diversified business model, strong cash flows, and consistent dividend increases position the company well for future growth despite facing headwinds [30][31]

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: HSBC upgraded UPS (UPS) to Buy from Hold with a price target of $125, up from $100. Q4 results beat expectations and while in-line 2026 guidance implies a weak Q1, it also points to strong margins by the end of 2026 when the Amazon (AMZN) glide down and tariff disruptions fade, the firm tells investors in a post ...

Core Viewpoint - Johnson & Johnson (JNJ) stock may be showing signs of recovery, indicating potential investment opportunities [1] Group 1: Company Overview - The article revisits Johnson & Johnson after a significant period, suggesting that the stock could be "waking up" [1] Group 2: Analyst Background - The author has a strong focus on the tech sector and holds a Bachelor of Commerce Degree with Distinction, majoring in Finance [1] - The author emphasizes core values of Excellence, Integrity, Transparency, and Respect as essential for long-term success [1] Group 3: Engagement with Readers - The author invites constructive criticism and feedback from readers to enhance the quality of future work [1]

Group 1: Company Overview - Johnson & Johnson (NYSE: JNJ) is a prominent healthcare company with a diverse product range in pharmaceuticals, medical devices, and consumer health, competing with major players like Pfizer and Merck [1] - The company's current trading price is $224.44, with a recent increase of $2.95, marking a 1.33% rise [4] - JNJ's market capitalization is approximately $540.7 billion, with a trading volume of 6,976,710 shares [4] Group 2: Financial Outlook - Johnson & Johnson has projected sales between $100 billion and $101 billion for 2026, exceeding the Zacks Consensus Estimate of $98.5 billion, indicating strong growth potential [2][6] - The company expects adjusted earnings per share to range from $11.43 to $11.63, reflecting confidence in its financial performance [2][6] Group 3: Segment Performance - The Innovative Medicine segment is anticipated to grow despite the loss of exclusivity for Stelara, driven by products like Darzalex and Tremfya, along with new product launches [3] - The MedTech segment is also expected to experience stronger growth, although it may face challenges from China's volume-based procurement policies [3] Group 4: Stock Performance - Over the past year, JNJ's stock price has fluctuated between a low of $141.50 and its current high of $224.44, reflecting the dynamic nature of the healthcare industry [5] - Morgan Stanley has set a price target of $262 for JNJ, suggesting a potential upside of 16.73% from its current trading price [1][6]

摩根士丹利：将强生(JNJ.N)目标价从200美元上调至262美元。 本文源自：金融界AI电报 ...

Core Insights - Amazon.ae is launching its annual Ramadan Sale from January 27 to February 14, featuring millions of deals across various categories including groceries, electronics, and fashion [1][8] Sales and Promotions - The sale will offer exclusive early access to Prime members starting January 27, with flexible payment options and instant bank discounts to enhance customer convenience during Ramadan [2][21] - Discounts of up to 50% are available on everyday essentials and groceries, with specific brands like Pampers and Nescafe included [10] - Kitchen and home appliances will see discounts of up to 50%, featuring brands such as Ninja and De'Longhi [11] - Electronics discounts reach up to 26% on items from brands like Samsung and Apple, while gaming products can be discounted by up to 29% [13] - Beauty and personal care products will have savings of up to 40%, with brands like L'Oreal Paris and Cetaphil participating [14][15] - Fashion items will be discounted by up to 35%, including brands like Calvin Klein and Michael Kors [16] Community and Social Responsibility - Amazon.ae is emphasizing community support during Ramadan, allowing customers to order Iftar boxes quickly via Amazon Now, which can also be sent to families in need [5][6][7] - The initiative aligns Amazon's logistics capabilities with social responsibility, reinforcing its commitment to value and social impact during the holy month [4][7] Delivery and Membership Benefits - Amazon Now offers rapid delivery options, with Prime members benefiting from free delivery on orders over Dhs25 and Rush 2-hour delivery on orders over Dhs100 [19][20] - Prime membership includes additional benefits such as free international delivery and access to Prime Video, available for Dhs16 per month or Dhs140 per year [20] Additional Savings Opportunities - Customers can maximize savings through instant bank discounts of up to 20% with specific credit cards, and Prime members can earn cashback on purchases [21][22] - Buy-Now, Pay-Later options are available, making larger purchases more manageable during the Ramadan season [22]

医药生物行业 行业研究 | 动态跟踪 IO 和 ADC 为焦点，联用将迎突破 ——JPM MNC 肿瘤进展梳理 核心观点 "一代 IO+ADC"和"二代 IO+化疗"均在今年读出 1L 驱动基因阴性 NSCLC 的关 键数据，届时在联用背景下，ADC 相对化疗，以及二代 IO 相对一代 IO 表现如何的 关键问题将得到解答，IO 联合 ADC 的确定性将显著提升。当前，IO 已开展和各种 ADC 的联用方案探索，在二代 IO 布局火热的同时，手握 ADC 产品的丰富程度或者 普适性可能亦是未来胜负的关键。因此，对于 ADC 的需求有望进一步提升。 投资建议与投资标的 风险提示 ⚫ 创新药研发失败的风险；市场竞争加剧的风险；创新药商业化的风险等。 国家/地区 中国 行业 医药生物行业 报告发布日期 2026 年 01 月 28 日 看好（维持） 伍云飞 执业证书编号：S0860524020001 香港证监会牌照：BRX199 wuyunfei1@orientsec.com.cn 021-63326320 | | hujuntao@orientsec.com.cn | | --- | --- | | 胡俊涛 | ...

营收941.93亿美元，同比增长6%——强生这份成绩单稳健的表象下，是一次被动的战略收缩：骨科业务增速跌至1.1%，成为医疗科技板块唯一失速的部 门，公司不得不宣布将DePuy Synthes分拆独立，以挽救整体估值体系。 最新！强生拟分拆骨科业务，又一百亿美元分拆案 相比之下，雅培443.28亿美元的营收体量虽仅为强生一半，却面临着更迫切的转型焦虑：IVD业务同比下滑4.3%，成为唯一失守的阵地。为此，公司豪掷 210亿美元收购Exact Sciences，试图用一场"并购式增长"填补新冠红利消退后的业绩真空。 01 顶级医疗"成绩单"公布 强生：心血管强势、骨科"最弱" 强生2025年全年营收941.93亿美元，同比增长6%， 其中： 创新制药业务： 是公司增长的主要引擎，占全年销售额的 65% 以上， 营 收604.01亿美元，同比增长6%。 医疗科技业务：营收337.92亿美元，同比增长6.1%。心血管业务以89.3亿美元销售额、15.8%的同比增速成为最大亮点，不仅是医疗技术部门中唯一实现 两位数增长的业务单元，更推动整体医疗器械业务迈向新高度。 | Full Year | | | | % Chan ...

中金研究 特朗普自2025年1月再次就任美国总统以来多次表示将采取措施推动美国药价降低，其多项举措与药企直接相关。根据ICER的报告，相比于2022年， 2024年经通胀调整后的新药标价（中位数）提高了24%，新药净价（中位数）提高了51%，药企的定价权依旧强势。总的来讲，我们认为，美国的高药 价与医保支付体系、PBM盈利机制，以及药企的定价权等因素密切相关，当前各方利益博弈之下，特朗普政府药价政策的实际效果与推进节奏存在不 确定性，影响相对有限。 点击小程序查看报告原文 美国医保体系的发展历程及现状 医疗服务成本高，医保覆盖率偏低 美国作为一个没有建立全民公共医保的发达国家，其以私人医疗保险为主体，市场力量为主导的医疗体系是一把双刃剑：一方面，通过市场竞争，将资金 与科技优势转化为医疗技术的发展，进而实现医疗产业的升级；另一方面，也导致当前美国医疗体系呈现出医疗服务成本高，医保覆盖面偏低，且医疗服 务效率有待提高的问题。 图表1：美国总医疗支出及其占GDP比重（1960-2023） 资料来源：CMS，中金公司研究部 ► 医疗服务成本： 在美国医疗总支出中，个人健康护理支出占绝对比重，其中，医院护理、专业医疗 ...

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPROо and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and relapsed/refractory multiple myeloma patients о HORSHAM, Pa., Jan. 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administ ...